Ras inhibition amplifies cisplatin sensitivity of human glioblastoma

Biochemical and Biophysical Research Communications

Volumn 320, Issue 2, 2004, Pages 493-500

  Messina, Samantha ^a,b   Leonetti, Carlo ^c   De Gregorio, Giorgia ^a   Affatigato, Valentina ^a   Ragona, Giuseppe ^a,b   Frati, Luigi ^a,b   Zupi, Gabriella ^c   Santoni, Angela ^a,b   Porcellini, Antonio ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Chemotherapy; Drug resistance; Gene therapy; Glioblastoma; Ras; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CISPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; EMBRYO; ENZYME INHIBITION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; ENZYME ACTIVATION; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 2942711576     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.06.003     Document Type: Article

References (26)

1. Bredel M., Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol. 3:2002;397-406
2. Inoue S., Salah-Eldin A.E., Omoteyama K. Apoptosis and anticancer drug resistance. Hum. Cell. 14:2001;211-221
3. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689
4. Guha A., Feldkamp M.M., Lau N., Boss G., Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 15:1997;2755-2765
5. A. Porcellini, D. De Blasi, Viral infection protocols, in: Methods in Molecular Biology, vol. 259, Humana press, Totowa, NY, 2004, pp. 155-166
6. Medema R.H., Wubbolts R., Bos J.L. Two dominant inhibitory mutants of p21ras interfere with insulin-induced gene expression. Mol. Cell. Biol. 11:1991;5963-5967
7. Citro G., D'Agnano I., Leonetti C., Perini R., Bucci B., Zon G., Calabretta B., Zupi G. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res. 58:1998;283-289
8. Kondo S., Barna B.P., Morimura T., Takeuchi J., Yuan J., Akbasak A., Barnett G.H. Interleukin-1 beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res. 55:1995;6166-6171
9. Quilliam L.A., Kato K., Rabun K.M., Hisaka M.M., Huff S.Y., Campbell-Burk S., Der C.J. Identification of residues critical for Ras(17N) growth-inhibitory phenotype and for Ras interaction with guanine nucleotide exchange factors. Mol. Cell. Biol. 14:1994;1113-1121
10. Stacey D.W., Feig L.A., Gibbs J.B. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol. Cell. Biol. 11:1991;4053-4064
11. Cool R.H., Schmidt G., Lenzen C.U., Prinz H., Vogt D., Wittinghofer A. The Ras mutant D119N is both dominant negative and activated. Mol. Cell. Biol. 19:1999;6297-6305
12. Matallanas D., Arozarena I., Berciano M.T., Aaronson D.S., Pellicer A., Lafarga M., Crespo P. Differences on the inhibitory specificities of H-Ras, K-Ras and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J. Biol. Chem. 278:2003;4572-4581
13. Fiordalisi J.J., Holly S.P., Johnson II R.L., Parise L.V., Cox A.D. A distinct class of dominant negative Ras mutants. Cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion. J. Biol. Chem. 277:2002;10813-10823
14. Feldkamp M.M., Lau N., Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 18:1999;7514-7526
15. Feldkamp M.M., Lau N., Roncari L., Guha A. Isotype-specific Ras. GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 2001;61-4425
16. Brazil D.P., Park J., Hemmings B.A. PKB binding proteins. Getting in on the Akt. Cell. 111:2002;293-303
17. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657
18. Grana T.M., Rusyn E.V., Zhou H., Sartor C.I., Cox A.D. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res. 62:2002;4142-4150
19. Chakravarti A., Chakladar A., Delaney M.A., Latham D.E., Loeffler J.S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a Ras-dependent manner. Cancer Res. 62:2002;4307-4315
20. Sanchez-Garcia I., Martin-Zanca D. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J. Mol. Biol. 267:1997;225-228
21. Nagame M., Levitzki A., Gazit A., Cavenee W.K., Huang H.-J.S. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA. 95:1998;5724-5729
22. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H., Louis D.N., Cavenee W.K., DePinho R.A. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15:2001;1311-1333
23. Fleming T.P., Saxena A., Clark W.C., Robertson J.T., Oldfield E.H., Aaronson S.A., Ali I.U. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52:1992;4550-4553
24. Lokker N.A., Sullivan C.M., Hollenbach S.J., Israel M.A., Giese N.A. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62:2002;3729-3735
25. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 2003;3-11
26. Stewart S., Guan The dominant negative Ras mutant, N17Ras, can inhibit signaling independently of blocking Ras activation. J. Biol. Chem. 2000;275-8854